1
|
Sánchez-Santos I, García-Sánchez GA, Gonzalez-Salinas R, Linares-Alba MA, Rodríguez-Reyes AA, García-Santisteban R, Tirado-González V, Hernández-Piñamora E, García-Arzate D, Morales-Cantón V, Quiroz-Mercado H. Intravitreal bromfenac liposomal suspension (100 μg / 0.1 ml). A safety study in rabbit eyes. Exp Eye Res 2020; 194:108020. [PMID: 32209318 DOI: 10.1016/j.exer.2020.108020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 03/19/2020] [Accepted: 03/20/2020] [Indexed: 12/18/2022]
Abstract
INTRODUCTION There is a need to find alternative treatments for MEe. Bromfenac has shown promise in inhibiting the COX-2 enzymatic pathway that partially causes the inflammatory cascade which contributes to the precipitation of ME. However, like other NSAID's, its intraocular half-life is limited. We hypothesize that a delayed-release liposome formulation containing bromfenac might provide a similar anti-inflammatory effect as long-lasting steroid release systems without the well-known steroidal side-effects. We introduced a novel formulation with these characteristics into the vitreous cavity of rabbit eyes in order to evaluate its safety profile. MATERIAL AND METHODS 10 left eyes of rabbits were injected with the liposome-encapsulated bromfenac suspension (100 μg/0.1 ml). Basal ERG's were recorded. Total follow-up time was 3 months, at which point ERG's were repeated and eyes were enucleated for histopathological study. Total amplitude and implicit times were recorded. A difference of 25% in either recording was considered significant. Significance was assessed using the paired-t test and Wilcoxon matched-pairs signed-rank test. A p-value of <0.05 was considered significant. RESULTS No significant changes were recorded in ERG measurements after 3 months when compared to basal measurements. Histopathological analysis of retinal specimens found no traces of liposome-induced toxicity. CONCLUSION The liposome-encapsulated bromfenac suspension (100 μg/0.1 ml) is not toxic and has been proven safe to use in an animal model. Therefore, this formulation shows promise as a possible future alternative treatment for ME and should be further studied to show its biological effect and efficacy.
Collapse
Affiliation(s)
- Idaira Sánchez-Santos
- Retina Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico.
| | - Gustavo A García-Sánchez
- Santgar Laboratory, México's master formulas SA, Augusto Rodin 35, Ampliación Nápoles, 03840, CDMX, Mexico
| | - Roberto Gonzalez-Salinas
- Retina Research Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | | | - Abelardo A Rodríguez-Reyes
- Ophthalmic Pathology Service, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | - Rodrigo García-Santisteban
- Retina Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | - Vanessa Tirado-González
- Retina Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | - Elsa Hernández-Piñamora
- Retina Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | - Daniel García-Arzate
- Retina Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | - Virgilio Morales-Cantón
- Retina Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| | - Hugo Quiroz-Mercado
- Retina Research Department, Asociación para evitar la Ceguera en México, Hospital ''Dr. Luis Sánchez Bulnes", Vicente García Torres 46, Barrio San lucas, 04030, Coyoacán, CDMX, Mexico
| |
Collapse
|